Skip to main content

Advertisement

Table 1 General parameters of the two groups

From: Feasibility of portal or superior mesenteric vein resection and reconstruction by allogeneic vein for pancreatic head cancer—a case-control study

Parameters Group A (n = 42) Group B (n = 42) P-value
Gender, case (%)    0.826
 Male 18 (42.9) 19 (45.2)  
 Female 24 (57.1) 23 (54.8)  
Age, year, median (range) 68 (43–80) 67 (45–79) 0.952
BMI, kg/m2, median, (range) 21.5 (17.6–28.6) 23.1 (17.3–29.7) 0.238
ASA Score (%)    0.608
 2 11 (26.2) 9 (21.4)  
 3 31 (73.8) 33 (78.6)  
Concomitant disease, case (%) 32 (76.2) 33 (78.6) 0.794
Abdominal operation history, case (%) 4 (9.5) 3 (7.1) 0.693
Preoperative biliary drainage, case (%) 8 (19.0) 7 (16.7) 0.776
Hemoglobin, g/L, median (range) 112.5 (86–153) 112.0 (87–151) 0.673
Total bilirubin, μmol/l, median (range) 84.9 (10.1–440) 79.4 (19.9–423) 0.989
Direct bilirubin, μmol/l, median (range) 64.1 (6.3–347) 69.8 (12.8–367) 0.733
Carbohydrate antigen 19–9, U/ml, median (range) 511.5 (2.0–6021) 493.4 (2.1–5966) 0.834
Tumor size, cm, median (range) 3.5 (2.0–5.0) 3.3 (2.0–5.0) 0.557
Tumor differentiation, case (%)    0.903
 Well 2 (4.8) 2 (4.8)  
 Moderate 24 (57.1) 22 (52.4)  
 Poor 16 (38.1) 18 (42.9)  
N stage, case (%)    0.728
 N0 4 (9.5) 5 (11.9)  
 N1 38 (90.5) 37 (88.1)  
Adjuvant therapy    0.977
 None 4 (9.5) 5 (11.9)  
 Gemcitabine 14 (33.3) 12 (28.6)  
 Gemcitabine+ Capecitabine 5 (11.9) 6 (14.3)  
 S1 12 (28.6) 11 (26.2)  
 FOLFIRINOX 7 (16.7) 8 (19.0)  
  1. ASA, American Society of Anesthesiology; BMI, body mass index; FOLFIRINOX, leucovorin and fluorouracil plus irinotecan and oxaliplatin